Key regions: United Kingdom, Canada, Japan, Europe, China
The demand for dermatological drugs in Ivory Coast has been on the rise in recent years.
Customer preferences: Ivory Coast has a population of over 25 million people, with a significant portion residing in urban areas. The population is becoming increasingly aware of the importance of skincare and is willing to invest in quality dermatological drugs. Customers in Ivory Coast prefer products that are affordable, effective, and easily accessible.
Trends in the market: The dermatological drugs market in Ivory Coast is experiencing significant growth due to several factors. Firstly, the country has a high prevalence of skin diseases such as eczema, psoriasis, and acne. This has led to an increase in demand for dermatological drugs. Secondly, the government has been investing heavily in the healthcare sector, leading to an increase in the availability of dermatological drugs. Thirdly, the rise of e-commerce platforms has made it easier for customers to access dermatological drugs.
Local special circumstances: Ivory Coast is a low-income country, and the majority of the population cannot afford expensive dermatological drugs. As a result, there is a high demand for affordable products. Additionally, the country has a tropical climate, which makes it prone to skin diseases. The high humidity levels and exposure to the sun can cause skin problems such as fungal infections and sunburn.
Underlying macroeconomic factors: The Ivory Coast economy has been growing steadily in recent years, with an average growth rate of 7% per annum. This has led to an increase in disposable income, which has enabled more people to afford dermatological drugs. Additionally, the government has been investing heavily in the healthcare sector, which has led to an increase in the availability of dermatological drugs. The rise of e-commerce platforms has also made it easier for customers to access dermatological drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
